Karyopharm Therapeutics Inc.

KPTI

$0.017

Name : Karyopharm Therapeutics Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $394,657.00

EPSttm : -14.33

Karyopharm Therapeutics Inc.

$0.017

0.00%

$0.00000000000000

KPTI — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

43.67

Margin Of Safety %

Put/Call OI Ratio

3.86

EPS Next Q Diff

1.11

EPS Last/This Y

12.09

EPS This/Next Y

3.02

Price

0.02

Target Price

Analyst Recom

Performance Q

-99.14

Upside

-2,289,100.0%

Beta

1.34

Ticker: KPTI

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-13	KPTI	0.4232	1.31	0.48	65744
2026-10-14	KPTI	0.3231	1.29	1.54	65689
2026-10-15	KPTI	0.3468	1.27	2.25	65444
2026-10-16	KPTI	0.3841	1.27	1.77	65356
2026-10-19	KPTI	0.3534	4.45	0.06	44346
2026-10-20	KPTI	0.3602	4.58	0.00	46524
2026-10-21	KPTI	0.425	4.51	0.00	46653
2026-10-22	KPTI	0.5499	4.32	0.88	47030
2026-10-23	KPTI	0.5015	4.23	0.06	47083
2026-10-26	KPTI	0.4832	4.16	0.00	47240
2026-10-27	KPTI	0.4717	4.06	0.10	47465
2026-10-28	KPTI	0.8321	4.03	6.86	47514
2026-10-29	KPTI	0.8606	4.27	0.49	52006
2026-10-30	KPTI	0.665	4.25	0.73	52903
2026-11-02	KPTI	0.1124	4.09	1.52	53672
2026-11-03	KPTI	0.0906	3.96	16.77	54166
2026-11-04	KPTI	0.077	3.92	0.45	53726
2026-11-05	KPTI	0.0614	3.87	0.37	53159
2026-11-06	KPTI	0.052	3.86	1.33	53168
2026-11-09	KPTI	0.0388	3.86	3.55	53157
2026-11-10	KPTI	0.017	3.86	1.21	53167
2026-11-11	KPTI	0.0174	3.86	1.21	53167
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-13	KPTI	0.43	65.6	-	-5.84
2026-10-14	KPTI	0.33	65.6	-	-5.84
2026-10-15	KPTI	0.35	65.6	-	-5.84
2026-10-16	KPTI	0.39	65.6	-	-5.84
2026-10-19	KPTI	0.35	65.6	-	-5.84
2026-10-20	KPTI	0.35	65.6	-	-5.84
2026-10-21	KPTI	0.36	65.6	-	-5.84
2026-10-22	KPTI	0.55	65.6	-	-5.84
2026-10-23	KPTI	0.51	65.6	-	-5.84
2026-10-26	KPTI	0.48	65.6	-	-5.84
2026-10-27	KPTI	0.47	65.6	-	-5.84
2026-10-28	KPTI	0.85	65.6	-	-5.84
2026-10-29	KPTI	0.87	65.6	-	-5.84
2026-10-30	KPTI	0.67	65.6	-	-5.84
2026-11-02	KPTI	0.11	65.6	-	-5.84
2026-11-03	KPTI	0.09	65.6	-	-5.84
2026-11-04	KPTI	0.08	65.6	-	-5.84
2026-11-05	KPTI	0.06	65.6	-	-5.84
2026-11-06	KPTI	0.05	65.6	-	-5.84
2026-11-09	KPTI	0.04	65.6	-	-5.84
2026-11-10	KPTI	0.02	65.6	-	-5.84
2026-11-11	KPTI	0.02	65.6	-	-5.84
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-13	KPTI	-0.12	14.31	32.13
2026-10-14	KPTI	-0.12	14.31	32.13
2026-10-15	KPTI	-0.12	14.31	32.13
2026-10-16	KPTI	-0.12	14.31	32.13
2026-10-19	KPTI	-0.25	11.40	32.13
2026-10-20	KPTI	-0.25	11.40	32.13
2026-10-21	KPTI	-0.25	11.40	32.13
2026-10-22	KPTI	-0.25	11.40	32.13
2026-10-23	KPTI	-0.23	11.40	32.13
2026-10-26	KPTI	-0.23	10.82	32.13
2026-10-27	KPTI	-0.24	10.82	38.55
2026-10-28	KPTI	-0.24	10.82	38.55
2026-10-29	KPTI	-0.23	10.82	38.55
2026-10-30	KPTI	-0.23	10.82	38.55
2026-11-02	KPTI	-0.23	10.82	38.55
2026-11-03	KPTI	-0.23	10.82	38.55
2026-11-05	KPTI	-0.24	10.82	38.55
2026-11-06	KPTI	-0.24	10.82	38.55
2026-11-09	KPTI	-0.23	9.67	38.55
2026-11-10	KPTI	-0.23	9.67	38.55
2026-11-11	KPTI	-0.23	9.67	43.67
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-2.32

Avg. EPS Est. Current Quarter

-1.31

Avg. EPS Est. Next Quarter

-1.21

Insider Transactions

-0.23

Institutional Transactions

9.67

Beta

1.34

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

100

Max Drawdown 5-Year %

-100

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

-13.08

Average EPS Est. Cur. Y

-5.84

EPS Next Y. (Est.)

-2.82

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-153.28

Relative Volume

Return on Equity vs Sector %

41.7

Return on Equity vs Industry %

61.3

EPS 1 7Days Diff

-1.1

EPS 1 30Days Diff

-0.89

EBIT Estimation

◆ KPTI Healthcare

$0.02

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

5/25

Volume

8/15

Valuation

12/20

TP/AR

2/10

Options

3/10

RSI

Range 1M

Sup Dist

35%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

22/30

Estimates

0/20

Inst/Vol

5/15

Options

1/10

EPS Yr

72.8%

EPS NY

80.8%

52W%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +74900% upside

Quality

7/30

Valuation

16/30

Growth

15/25

Stability

6/10

LT Trend

1/5

Upside

+74900%

Quality

KPTI — P/E HistoricalBiotechnology

Karyopharm Therapeutics Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 228

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. On November 2, 2026, Karyopharm Therapeutics Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

KPTI

Latest News

—

Caricamento notizie per KPTI…

stock quote shares KPTI – Karyopharm Therapeutics Inc Stock Price stock today

news today KPTI – Karyopharm Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch KPTI – Karyopharm Therapeutics Inc yahoo finance google finance

stock history KPTI – Karyopharm Therapeutics Inc invest stock market

stock prices KPTI premarket after hours

ticker KPTI fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: KPTI

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y